Drug Trial Radar · NCT01307098
Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency
Last checked: Nov 20, 2026Latest source record: Dec 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Apr 25, 2011
Primary completion
Jan 6, 2012
Study completion Jan 6, 2012
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 2, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was the first clinical study of SBC-102 (sebelipase alfa) for the treatment of Lysosomal Acid Lipase (LAL) Deficiency. It was an open-label dose escalation study in adult participants with liver dysfunction due to LAL Deficiency and was designed to examine 3 doses of sebelipase alfa. The targeted number for this study was 9 evaluable participants.
Conditions
- Cholesterol Ester Storage Disease(CESD)
- Lysosomal Acid Lipase Deficiency
- LAL-Deficiency
Interventions
Sebelipase alfa 0.35 mg/kgDrug
Sebelipase alfa is a recombinant human lysosomal acid lipase.
Sebelipase alfa 1 mg/kgDrug
Sebelipase alfa is a recombinant human lysosomal acid lipase.
Sebelipase alfa 3 mg/kgDrug
Sebelipase alfa is a recombinant human lysosomal acid lipase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number Of Participants Reporting TEAEs And Infusion-Related Reactions (IRRs)Time frame: Screening up to Day 52
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Stanford, California
Site not named
New York, New York
Site not named
Pittsburgh, Pennsylvania
Site not named
Prague, Czechia
Site not named
Paris, France
Site not named
Cambridge, United Kingdom
Site not named
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.